November 17, 2022
FDA: Class I recall of Insulet Omnipod DASH PDM
Editor's Note
The Food and Drug Administration (FDA) on November 16 identified the recall by Insulet of its Omnipod DASH Insulin Management System Personal Diabetes Manager (PDM) as Class I, the most serious.
The recall was initiated because of PDM battery issues, including:
- Battery swelling
- Fluid leakage from the battery
- Extreme overheating that may pose a fire hazard.
The company reports 455 complaints, three fires, and no injuries or deaths.
Distribution dates were July 27, 2018, to August 31, 2022.
Free Daily News
- New studies highlight opportunities to improve pediatric anesthesia safety, comfort
- Social and behavioral factors emerging as key predictors of recovery quality after surgery
- Hospitals being squeezed: Anesthesia workforce gaps, payer cuts threaten surgery access
- CDC layoffs cripple national injury and overdose tracking, leaving prevention efforts in doubt
- The Joint Commission makes nurse staffing a national performance goal for 2026
- Telehealth in limbo: Providers split on continuing Medicare services during shutdown
- States take aim at outpatient facility fees driving higher commercial health costs
- Slower acquisitions, mounting debt reshape Surgery Partners growth outlook
- ASCs surge as hospitals and investors chase outpatient growth
- Nearly half of US physicians now work for large systems: GAO links consolidation to higher costs
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement